Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice

The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the intravesical administration of live Mycobacterium bovis BCG. Previous studies suggest improving this therapy by implementing non-pathogenic mycobacteria, such as Mycobacterium brumae, and/or different vehicles for my...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguera-Ortega, Estela, Rabanal, Rosa M., Gómez-Mora, Elisabet, Cabrera, Cecilia, Luquin, Marina, Julián, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180069/
https://www.ncbi.nlm.nih.gov/pubmed/30305693
http://dx.doi.org/10.1038/s41598-018-33253-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180069/
https://www.ncbi.nlm.nih.gov/pubmed/30305693
http://dx.doi.org/10.1038/s41598-018-33253-w

Ejemplares similares